Manchester, UK, February XX, 2023– NEPeSMO Ltd, a pioneer in AI-driven, self-monitoring solutions for the prediction of exacerbations in patients with chronic lung diseases is pleased to announce the agreement of a sponsorship by GlaxoSmithKline UK Limited (GSK) enabling for up to 1000 patients with COPD access to COPDPredict™ in the UK for 6 months.
Trevor Phillips, CEO of NEPeSMO commented “we are delighted for GSK’s sponsorship of the delivery of COPDPredict™ into the NHS. GSK’s sponsorship is in recognition of both the novel solution provided by COPDPredict™ and the value that smart remote patient monitoring can offer for patients and clinicians in the management of COPD.”
About COPDPredict™: COPDPredict™ creates unique personalised bio-clinical profiles from a combination of simple, routinely collected patient-reported symptoms, physiological and biomarker tests. From this data, proprietary exacerbation prediction algorithms identify changes in COPD health status, alerting patients and their clinicians of an impending exacerbation. Unlike other digital health trackers and adherence monitors, COPDPredict™ gives patients and clinicians the opportunity to adjust treatment promptly with a view to reduce the risk of hospitalisations.
A National Institute for Health and Care Research funded study on 90 patients (age range 48 to 91yrs; FEV1 15 to 86% predicted) with at least 1 hospitalisation in prior 6 months demonstrated that COPDPredict™ identified impending exacerbations of COPD with high sensitivity and specificity, leading to significant reduction in hospitalisations (Patel N et al. Validation of COPDPredict™: Unique combination of Remote Monitoring and Exacerbation Prediction to support preventative management of COPD exacerbations. Int J of Chron Obstruct Pulmon Dis 2021:16; 1887‐1899).
GSK has not been involved in the development of COPDPredict™. GSK is sponsoring the delivery of COPDPredict™ to a fixed number of COPD patients. GSK is involved in the scoping and supporting of project delivery and evaluation and will review all materials and COPDPredict™ for compliance with applicable laws and regulations.
Contacts: With regards to the announcement please contact Trevor Phillips, Chairman & Chief Executive Officer (email@example.com).